Skip to the main content

Reumatizam, Vol. 54 No. 2, 2007.

Conference paper

Etanercept (Enbrel®) - our experiences

Jadranka Morović-Vergles ; Department for Clinical Immunology and Rheumatology, Clinic for Internal Medicine, Clinical Hospital “Dubrava”, Zagreb, Croatia
Dušanka Martinović Kaliterna ; Department for Clinical Immunology and Rheumatology, Clinic for Internal Medicine, Clinical Hospital Centre Split, Split, Croatia

Full text: croatian pdf 426 Kb

page 69-70

downloads: 351

cite

Abstract

Rheumatoid arthritis (RA) is a chronic, systemic disease. Female patients outnumber males in a ratio of 3:1. Cytokines and immune cells networks have been identified as important mediators in the pathogenesis and perpetuation of inflammation in RA. This information has been successfully used into the development of new and significantly more effective treatments, for example anticytokines agents. The goal in managing RA is to achieve remission. We report five patients with RA successfully treated with etanercept.

Keywords

etanercept; rheumatoid arthritis; disease activity score 28 (DAS28)

Hrčak ID:

125352

URI

https://hrcak.srce.hr/125352

Publication date:

19.10.2007.

Article data in other languages: croatian

Visits: 1.813 *